Savara (NASDAQ:SVRA) Given New $15.00 Price Target at Oppenheimer

Savara (NASDAQ:SVRA) had its price objective lifted by Oppenheimer from $11.00 to $15.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also recently weighed in on SVRA. Evercore ISI cut their price target on shares of Savara from $10.00 to $7.00 and set an outperform rating on the stock in a report on Thursday, May 16th. Piper Sandler lifted their price target on Savara from $7.00 to $16.00 and gave the stock an overweight rating in a report on Monday, March 4th. JMP Securities reaffirmed a market outperform rating and set a $8.00 target price on shares of Savara in a research report on Monday, May 6th. Finally, HC Wainwright restated a buy rating and set a $6.00 price objective on shares of Savara in a report on Monday, May 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of Buy and a consensus price target of $9.83.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $3.84 on Wednesday. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. The stock’s 50 day moving average is $4.36 and its 200-day moving average is $4.64. Savara has a twelve month low of $2.60 and a twelve month high of $5.70. The firm has a market capitalization of $530.65 million, a price-to-earnings ratio of -10.38 and a beta of 0.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Sell-side analysts forecast that Savara will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. purchased a new position in shares of Savara in the first quarter worth about $4,258,000. California State Teachers Retirement System boosted its holdings in Savara by 411.0% in the 1st quarter. California State Teachers Retirement System now owns 75,986 shares of the company’s stock worth $378,000 after buying an additional 61,117 shares during the period. AWM Investment Company Inc. purchased a new position in Savara in the 1st quarter valued at approximately $498,000. Janus Henderson Group PLC raised its holdings in Savara by 41.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after acquiring an additional 746,407 shares during the period. Finally, Bain Capital Life Sciences Investors LLC raised its holdings in Savara by 2.3% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after acquiring an additional 332,706 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.